Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxidative Phosphorylation Targeting in Malignant Glioma Using Metformin Plus Radiotherapy and Temozolomide
2021-000192-37Phase 2Active
- Sponsor
- Hôpital Foch
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of metformin in glioblastoma (GBM), sponsored by Hôpital Foch. Primary endpoint: Progression-free survival. Started May 2021; status: active.
02
Drugs
metformin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2021-000192-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000192-37.